Y F Chemical, which holds a 70% market share of infusion solutions in Taiwan, has been ordered to shut down by regulatory authorities due to violations of PIC/S GMP standards. This closure has led to a severe shortage of saline, glucose, and other infusion solutions across Taiwan. Nang Kuang Pharmacecutical andChi Sheng Pharma & Biotech are ramping up production to prevent a crisis that could disrupt surgeries and hospitalizations nationwide.
The shutdown of Y F Chemical’s operations presents an opportunity for Nang Kuang Pharmacecutical andChi Sheng Pharma & Biotech to penetrate large medical centers and benefit from redirected orders. This has positively impacted their stock prices, which surged to their daily limit on the 20th. Analysts predict that this situation will directly boost both companies' revenues, providing significant operational momentum.
The Taiwan Food and Drug Administration (TFDA) mandated the closure of Y F Chemical’s Xinzhuang factory due to severe violations of PIC/S GMP standards, requiring corrective actions that were not addressed by the company. The manufacturing license expired on May 10, leading to the enforced closure by the authorities. In response to the anticipated drug shortage, the TFDA has coordinated with domestic pharmaceutical companies to increase production capacity.
Y F Chemical’s infusion products account for a 70% market share in Taiwan. The shutdown has created a supply gap for essential products such as saline, glucose, and sterile solutions, critical for surgeries, dialysis, and hospitalizations. Current inventories are expected to last until June. To address this shortfall, Nang Kuang Pharmacecutical andChi Sheng Pharma & Biotech are actively boosting their production capacities, striving to fill the gap left by Y F Chemical.
Resource (Mandarin):
